Filter
71
Featured
9
8
Language
Document type
38
16
8
3
2
2
1
1
Countries / Regions
2
2
2
2
2
2
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
35
4
1
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB,
...
The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci
...
La infección latente por tuberculosis (ILTB) es un estado de respuesta inmunitaria persistente a la estimulación por antígenos de Mycobacterium tuberculosis sin indicios de manifestaciones clínicas de tuberculosis activa
Руководство по инвестициям Глобального фонда для стран Восточной Европы и Центральной Азии. В ходе разработки Руководства Глобальный фонд стремился учесть мнени
...
ПЛАНИРОВАНИЕ И МОНИТОРИНГ ПРОГРЕССА НА ПУТИ К ЭЛИМИНАЦИИ
Guide des éléments essentiels pour une bonne pratique - Première édition 2019
Ce guide a été conçu afin d’apporter les informations nécessaires à une prise en charge pratique et exhaustive des personnes atteintes de diabète et de tuberculose. Il s’appuie sur les résultats d’étude
...
Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income CountriesThe practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide.
The third edition, released in 2018, has grown to include a total of 18 chapters, contributed by 20 experts and authors from many countries. The goal remains the same: to educate primary care providers on the best practices in TB diagnosis, treatment and follow-up. All articles are richly illustrate
...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Презентация о туберкулезе и диабете
Цей документ описує кроки, необхідні для визначення скоригованого інтервалу QT (QTc) в
ході моніторингу ЕКГ пацієнтів, які отримують препарати для лікування ХР ТБ, що
...
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
Este documento presenta modelos de algoritmos que permiten investigar por métodos bacteriológicos a los pacientes para el diagnóstico de tuberculosis (TB), TB asociada al Virus de Inmunodeficiencia Humana (TB-HIV) y TB drogorresistente (TBDR).
Guidelines for treatment of drug-susceptible tuberculosis and patient care
2017 update
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
